Effects of Valvular Heart Disease on Clinical Outcomes in Sarcoidosis

Curr Probl Cardiol. 2023 Oct;48(10):101866. doi: 10.1016/j.cpcardiol.2023.101866. Epub 2023 Jun 8.

Abstract

Systemic sarcoidosis can lead to heart failure, conduction abnormalities and ventricular arrhythmias although data on concomitant valvular heart disease (VHD) is limited. We reported the prevalence and outcomes of VHD in systemic sarcoidosis. A retrospective cohort study was conducted using National Inpatient Sample between 2016 and 2020 with respective ICD-10-CM codes. 406,315 patients were hospitalized with sarcoidosis, out of which 20,570 had comorbid VHD (5.1%). Mitral disease was most common (2.5%), followed by aortic, and tricuspid disease. Tricuspid disease was associated with increased mortality in sarcoidosis (OR 1.6, 95% CI, 1.1-2.6, P = 0.04), while aortic disease was associated with higher mortality in only 31-50 years age cohort. Patients with sarcoidosis and VHD have higher hospitalization charges and lower or similar valvular intervention rates than those without sarcoidosis. VHD has a prevalence of 5% in sarcoidosis, predominantly affecting mitral and aortic valves. Underlying VHD is associated with worse outcomes in sarcoidosis.

Publication types

  • Review

MeSH terms

  • Anticoagulants
  • Atrial Fibrillation* / epidemiology
  • Heart Valve Diseases* / epidemiology
  • Humans
  • Retrospective Studies
  • Sarcoidosis* / complications
  • Sarcoidosis* / diagnosis
  • Sarcoidosis* / epidemiology

Substances

  • Anticoagulants